Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
“Finalizing our exclusive agreement with EVERSANA is a transformative milestone as we prepare and plan to bring LYMPHIR to market in Q4 2025,” said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharma. “As a lean and strategically focused organization, this agreement allows us to significantly extend our commercial capabilities by leveraging EVERSANA’s best-in-class infrastructure and deep expertise in oncology commercialization. EVERSANA’s demonstrated ability to execute across the product lifecycle enhances our ability to scale efficiently, ensure timely market access for LYMPHIR, and support a high-quality launch aligned with investor expectations. We believe this collaboration strengthens our operational readiness, de-risks execution, and enhances our capacity to generate long-term value for shareholders.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo